TFE3 immunohistochemistry in renal cell carcinomas: does the clone really matter?
Northern Clinics of Istanbul · 2025 · 438-444
DOI: 10.14744/nci.2024.19794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Northern Clinics of Istanbul, 2025. Verfasst von Tuba Dilay Kokenek Unal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: TFE3 rearranged carcinomas constitute 5% of malignant tumours of the kidney in adults. TFE3 immunohistochemistry plays a crucial role in the diagnosis. TFE3 positivity in the appropriate histological context supports the diagnosis of Xp11 translocation renal cell carcinomas. However, there isn't any standardized approach to performing and interpreting immunohistochemical staining. METHODS: A total of 51 renal cell carcinomas are included in the study. In this study, we compared the expression profiles of two different anti-TFE3 antibody clones (MRQ37, Cell Marque, and IHC627, GeneAbTM) on renal cell carcinoma samples that have conflicting morphologies and assessed the overall performance of these clones to identify TFE3 rearranged carcinomas. RESULTS: There was a statistically significant difference in terms of immunohistochemical staining with TFE3-MRQ37 clone between TFE3 rearranged renal cell carcinomas and other subtypes, while no significant difference was found in staining with TFE3-IHC672. 47% of cases were stained with the TFE3-IHC672 clone and 9.8 % of cases were stained with the TFE3-MRQ37 clone at different staining intensities and proportions. CONCLUSION: The TFE3-MRQ37 clone is easier to interpret because of the absence of background staining and is more reliable in identifying TFE3 rearranged renal cell carcinomas. However, because of various sensitivity and specificity rates, and immunoreactivity in many subtypes of renal cell carcinomas, there is a need for a standardised approach for TFE3 immunohistochemistry for diagnostic use in TFE3-tRCCs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkiye.
- Department of Pathology, Ankara Bilkent City Hospital, Ankara, Turkiye.
- Department of Pathology, University of Health Sciences, Ankara, Turkiye.
- Department of Pathology, Lokman Hekim University Faculty of Medicine, Ankara, Turkiye.
Zitieren
APA
Unal, T. D. K., Kiran, M. M., Sungu, N., Yazgan, A., & Gumuskaya, B. (2025). TFE3 immunohistochemistry in renal cell carcinomas: does the clone really matter?. Northern Clinics of Istanbul, 438-444. https://doi.org/10.14744/nci.2024.19794
Vancouver
Unal TDK, Kiran MM, Sungu N, Yazgan A, Gumuskaya B. TFE3 immunohistochemistry in renal cell carcinomas: does the clone really matter?. Northern Clinics of Istanbul. 2025:438-444. doi:10.14744/nci.2024.19794
BibTeX
@article{Unal2025,
author = {Unal, Tuba Dilay Kokenek and Kiran, Merve Meryem and Sungu, Nuran and Yazgan, Aylin and Gumuskaya, Berrak},
title = {TFE3 immunohistochemistry in renal cell carcinomas: does the clone really matter?},
journal = {Northern Clinics of Istanbul},
year = {2025},
pages = {438--444},
doi = {10.14744/nci.2024.19794}
}
EUVIMED